Sana Biotechnology Announces FDA Clearance of Investigational …
Nov 9, 2023 · Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, …
Sana Biotechnology Reports Third Quarter 2023 Financial Results …
SEATTLE, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today …
Sana Biotechnology Announces Preclinical Data Published in …
SEATTLE, May 08, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today …
Sana Biotechnology Announces the Acceptance of Six Abstracts …
May 2, 2023 · Process improvements were made to the manufacturing of Sana’s CD8 targeted fusosome for in vivo CAR T therapy, resulting in enhanced resting T cell transduction and in …
Investor Relations | Sana Biotechnology, Inc
Dec 2, 2024 · The Investor Relations website contains information about Sana Biotechnology, Inc's business for stockholders, potential investors, and financial analysts.
Release Details - Sana Biotechnology, Inc
SEATTLE, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today …
Sana Biotechnology, Inc News Releases
Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across …
Sana Biotechnology to Present at the Goldman Sachs Cell Therapy …
SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today …
Sana Biotechnology to Present at November and December 2023 …
SEATTLE, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today …
Sana Biotechnology Announces Preclinical Data Published in …
Apr 13, 2023 · Sana Biotechnology Announces Preclinical Data Published in Nature Communications Demonstrating the Ability of its Hypoimmune Allogeneic CD19-directed CAR …